Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
AN2 Therapeutics, Inc. shareholders approved Ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-03 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-06-03
Exact text from the filing
2. To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The voting results were as follows: Votes For Votes Against Abstentions 22,724,674 13 16,848
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
AN2 Therapeutics, Inc. shareholders approved Election of the nominees Kabeer Aziz, Gilbert Lynn Marks, M.D. and Rob Readnour, Ph.D. as Class I directors at the 2026-06-03 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-06-03
Exact text from the filing
1. To elect the nominees Kabeer Aziz, Gilbert Lynn Marks, M.D. and Rob Readnour, Ph.D. as Class I directors until the Company’s 2029 annual meeting of stockholders or until their respective successors have been elected or appointed. The voting results were as follows: Name Votes For Votes Withheld Broker Non-Votes Kabeer Aziz 13,547,536 3,958,874 5,235,125 Gilbert Lynn Marks, M.D. 15,947,854 1,558,556 5,235,125 Rob Readnour, Ph.D. 15,920,563 1,585,847 5,235,125
View on SEC.gov